600079 ST人福
午间休市 11-12 11:29:57
资讯
新帖
简况
ST人福(600079.SH):HW281171片获得药物临床试验批准通知书
智通财经 · 11-10 16:15
ST人福(600079.SH):HW281171片获得药物临床试验批准通知书
股市必读:ST人福三季报 - 第三季度单季净利润同比增长103.27%
证券之星 · 11-02
股市必读:ST人福三季报 - 第三季度单季净利润同比增长103.27%
ST人福(600079)披露2026年第三季度报告,10月29日股价下跌0.56%
证券之星 · 10-29
ST人福(600079)披露2026年第三季度报告,10月29日股价下跌0.56%
ST人福:关于新疆维吾尔族特色药品的购买,建议通过正规医疗机构处方及授权药店渠道进行购买
证券之星 · 10-29
ST人福:关于新疆维吾尔族特色药品的购买,建议通过正规医疗机构处方及授权药店渠道进行购买
ST人福:公司医药研究院已在上海组建专业团队
证券之星 · 10-29
ST人福:公司医药研究院已在上海组建专业团队
百亿资金占用罚单落地,ST人福索赔窗口开启
市场资讯 · 10-29
百亿资金占用罚单落地,ST人福索赔窗口开启
ST人福(600079)10月26日主力资金净买入1740.75万元
证券之星 · 10-26
ST人福(600079)10月26日主力资金净买入1740.75万元
股市必读:ST人福新发布《关于芦比前列酮软胶囊获得美国FDA批准文号的公告》
证券之星 · 10-21
股市必读:ST人福新发布《关于芦比前列酮软胶囊获得美国FDA批准文号的公告》
ST人福(600079.SH):芦比前列酮软胶囊获得美国FDA批准文号
智通财经 · 10-19
ST人福(600079.SH):芦比前列酮软胶囊获得美国FDA批准文号
ST人福(600079)10月19日主力资金净买入3970.37万元
证券之星 · 10-19
ST人福(600079)10月19日主力资金净买入3970.37万元
ST人福(600079)10月16日主力资金净卖出4571.56万元
证券之星 · 10-16
ST人福(600079)10月16日主力资金净卖出4571.56万元
股市必读:ST人福新发布《关于舒更葡糖钠注射液获得英国药品和健康产品监管局(MHRA)上市许可的公告》
证券之星 · 10-15
股市必读:ST人福新发布《关于舒更葡糖钠注射液获得英国药品和健康产品监管局(MHRA)上市许可的公告》
ST人福(600079.SH):舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可
智通财经 · 10-13
ST人福(600079.SH):舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可
ST人福(600079)10月12日主力资金净买入1259.75万元
证券之星 · 10-12
ST人福(600079)10月12日主力资金净买入1259.75万元
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
证券之星 · 10-12
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
证券之星 · 10-09
股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》
ST人福(600079)披露2026年度向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺(二次修订稿)的公告,9月29日股价上涨0.11%
证券之星 · 09-29
ST人福(600079)披露2026年度向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺(二次修订稿)的公告,9月29日股价上涨0.11%
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
证券之星 · 09-28
股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复》
ST人福(600079)披露2026年度向特定对象发行A股股票募集说明书(申报稿),9月23日股价上涨0.53%
证券之星 · 09-23
ST人福(600079)披露2026年度向特定对象发行A股股票募集说明书(申报稿),9月23日股价上涨0.53%
每周股票复盘:ST人福(600079)间苯三酚口崩片获注册证书
证券之星 · 09-13
每周股票复盘:ST人福(600079)间苯三酚口崩片获注册证书
暂无数据
公司概况
公司名称:
人福医药集团股份公司
所属行业:
医药制造业
上市日期:
1997-06-06
主营业务:
人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、黄体酮原料药、祖卡木颗粒、复方木尼孜其颗粒。公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。
发行价格:
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":19.77,"timestamp":1794454197000,"preClose":19.54,"halted":0,"volume":10860100,"delay":0,"changeRate":0.0118,"floatShares":1543000000,"shares":1632000000,"eps":1.5817,"marketStatus":"午间休市","change":0.23,"latestTime":"11-12 11:29:57","open":19.5,"high":19.94,"low":19.31,"amount":213000000,"amplitude":0.0322,"askPrice":19.78,"askSize":218,"bidPrice":19.77,"bidSize":23,"shortable":0,"etf":0,"ttmEps":1.5817,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794459600000},"marketStatusCode":3,"adr":0,"adjPreClose":19.54,"symbolType":"stock","openAndCloseTimeList":[[1794447000000,1794454200000],[1794459600000,1794466800000]],"highLimit":20.52,"lowLimit":18.56,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":12.49921,"roe":"12.21%","epsLYR":1.14,"committee":-0.111402,"marketValue":32269000000,"turnoverRate":0.007,"status":0,"floatMarketCap":30509000000},"requestUrl":"/m/hq/s/600079/tweets","defaultTab":"tweets","newsList":[{"id":"2682362336","title":"ST人福(600079.SH):HW281171片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2682362336","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682362336?lang=zh_cn&edition=full","pubTime":"2026-11-10 16:15","pubTimestamp":1794298536,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司湖北生物医药产业技术研究院有限公司(简称“研究院有限公司”)近日收到国家药品监督管理局核准签发的HW281171片的《药物临床试验批准通知书》。HW281171片拟用于慢性荨麻疹的治疗,是一款口服的小分子新药。截至目前,该项目累计研发投入约为3,000万元人民币。荨麻疹是由于皮肤、黏膜小血管扩张及渗透性增加出现的一种局限性水肿反应,该病病程迁延反复且疾病负担较重,顽固性剧烈瘙痒严重干扰患者的睡眠质量与心理健康。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IBBQ","BK0028","IBBJ","BK0188","BK0185","BK0012","BK0070","MDTX","BK0096","PSYK","BK0239","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680207523","title":"股市必读:ST人福三季报 - 第三季度单季净利润同比增长103.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680207523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680207523?lang=zh_cn&edition=full","pubTime":"2026-11-02 02:24","pubTimestamp":1793557482,"startTime":"0","endTime":"0","summary":"公司公告汇总2026年第三季度报告2026年第三季度营业收入6,351,737,001.06元,同比增长9.15%;利润总额1,491,892,719.34元,同比增长77.09%;归属于上市公司股东的净利润1,085,268,724.45元,同比增长103.27%。年初至报告期末营业收入18,412,438,760.89元,同比增长2.96%;利润总额3,488,273,002.28元,同比增长32.55%;归属于上市公司股东的净利润2,414,822,681.44元,同比增长43.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200000595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679272285","title":"ST人福(600079)披露2026年第三季度报告,10月29日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679272285","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679272285?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:08","pubTimestamp":1793282911,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘,ST人福报收于19.45元,较前一交易日下跌0.56%,最新总市值为317.47亿元。近日,ST人福披露《2026年第三季度报告》。报告显示,本报告期营业收入6,351,737,001.06元,同比增长9.15%;利润总额1,491,892,719.34元,同比增长77.09%;归属于上市公司股东的净利润1,085,268,724.45元,同比增长103.27%。年初至报告期末营业收入18,412,438,760.89元,同比增长2.96%;利润总额3,488,273,002.28元,同比增长32.55%;归属于上市公司股东的净利润2,414,822,681.44元,同比增长43.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900062761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK0070","BK0012","BK0028","600079","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679474745","title":"ST人福:关于新疆维吾尔族特色药品的购买,建议通过正规医疗机构处方及授权药店渠道进行购买","url":"https://stock-news.laohu8.com/highlight/detail?id=2679474745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679474745?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:18","pubTimestamp":1793269096,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问:内陆省份如何购买新疆维吾尔族特色药?ST人福回复:答:尊敬的投资者,您好!关于新疆维吾尔族特色药品的购买,建议通过正规医疗机构处方及授权药店渠道进行购买。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900043455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0028","BK0185","BK0096","BK0012","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679474710","title":"ST人福:公司医药研究院已在上海组建专业团队","url":"https://stock-news.laohu8.com/highlight/detail?id=2679474710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679474710?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:18","pubTimestamp":1793269096,"startTime":"0","endTime":"0","summary":"证券之星消息,ST人福(600079)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问:公司有在上海设立药物研究院或类似科研机构吗?ST人福回复:答:尊敬的投资者,您好!公司医药研究院已在上海组建专业团队,主要负责商务拓展、临床运营管理等工作。感谢您对公司的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900043456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0012","BK0070","600079","159938","BK0028","BK0185","BK0096","BK0239","BK1161","BK0188","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679479827","title":"百亿资金占用罚单落地,ST人福索赔窗口开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2679479827","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679479827?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:11","pubTimestamp":1793265060,"startTime":"0","endTime":"0","summary":"处罚决定书显示:2020年至2022年3月,在原控股股东要求和安排下,公司与其发生非经营性资金占用,累计发生额高达127.85亿元,其中2021年度占用81.79亿元,占最近一期经审计净资产的62.97%。值得留意的是,2025年7月,央企背景的招商局集团已通过司法重整入主公司——百亿占用的旧账正由监管处罚与民事索赔“算总账”,新主入主也让赔付能力与责任承担更具可期待性。团队采取全风险代理,获赔前不产生任何费用。最终以法院认定为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-10-29/doc-iniwwtuv8822823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0185","BK0012","BK0028","600079","BK0070","BK0188","BK0239","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678157514","title":"ST人福(600079)10月26日主力资金净买入1740.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678157514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678157514?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:25","pubTimestamp":1792999519,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月26日收盘,ST人福报收于19.7元,上涨2.18%,换手率0.75%,成交量11.6万手,成交额2.26亿元。10月26日的资金流向数据方面,主力资金净流入1740.75万元,占总成交额7.69%,游资资金净流出1710.06万元,占总成交额7.55%,散户资金净流出30.69万元,占总成交额0.14%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600014655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0188","BK0070","BK0012","BK0239","600079","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677362618","title":"股市必读:ST人福新发布《关于芦比前列酮软胶囊获得美国FDA批准文号的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677362618","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677362618?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:17","pubTimestamp":1792516627,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘,ST人福报收于19.55元,上涨1.3%,换手率0.89%,成交量13.71万手,成交额2.67亿元。当日关注点交易信息汇总:10月20日主力资金净流入1262.52万元,占总成交额4.73%。公司公告汇总:芦比前列酮软胶囊获美国FDA批准,获批用于成人慢性特发性便秘、阿片类药物诱导便秘及18岁及以上女性便秘型肠易激综合征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0185","BK0096","BK0070","600079","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676394506","title":"ST人福(600079.SH):芦比前列酮软胶囊获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2676394506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676394506?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:49","pubTimestamp":1792396152,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,公司全资子公司人福普克药业(武汉)有限公司(简称“人福普克”)近日收到美国食品药品监督管理局(FDA)关于芦比前列酮软胶囊的批准文号。芦比前列酮软胶囊被批准用于治疗:(1)成人慢性特发性便秘(CIC);(2)用于伴有慢性非癌性疼痛的成人患者的阿片类药物诱导便秘(OIC),包括既往罹患癌症或癌症治疗相关慢性疼痛、且无需频繁(如每周)上调阿片类药物剂量的患者;(3)用于18岁及以上女性便秘型肠易激综合征(IBS‑C)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0070","600079","BK4588","BK0096","BK0012","BK4585","BK0188","BK0239","LABU","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676055325","title":"ST人福(600079)10月19日主力资金净买入3970.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676055325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676055325?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:23","pubTimestamp":1792394590,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月19日收盘,ST人福报收于19.3元,上涨2.17%,换手率1.48%,成交量22.87万手,成交额4.42亿元。10月19日的资金流向数据方面,主力资金净流入3970.37万元,占总成交额8.99%,游资资金净流出3175.95万元,占总成交额7.19%,散户资金净流出794.42万元,占总成交额1.8%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900013080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0188","BK0070","BK0012","BK0239","600079","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675613125","title":"ST人福(600079)10月16日主力资金净卖出4571.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675613125","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675613125?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:23","pubTimestamp":1792135434,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月16日收盘,ST人福报收于18.89元,下跌5.5%,换手率3.53%,成交量54.45万手,成交额10.73亿元。10月16日的资金流向数据方面,主力资金净流出4571.56万元,占总成交额4.26%,游资资金净流入50.28万元,占总成交额0.05%,散户资金净流入4521.28万元,占总成交额4.21%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600020782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","600079","BK0096","BK0188","BK0028","BK0239","BK0012","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675293113","title":"股市必读:ST人福新发布《关于舒更葡糖钠注射液获得英国药品和健康产品监管局(MHRA)上市许可的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675293113","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675293113?lang=zh_cn&edition=full","pubTime":"2026-10-15 01:14","pubTimestamp":1791998051,"startTime":"0","endTime":"0","summary":"公司公告汇总:舒更葡糖钠注射液获英国MHRA上市许可,有效期5年,2025年英国市场年销售额约8500万美元。公司公告汇总关于舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可的公告人福医药集团股份公司控股子公司宜昌人福药业有限责任公司收到英国药品和健康产品监管局核准签发的舒更葡糖钠注射液上市许可批准信,获准在英国销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0096","BK0012","BK0070","BK0239","BK0188","BK0028","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675331112","title":"ST人福(600079.SH):舒更葡糖钠注射液获得英国药品和健康产品监管局上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2675331112","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675331112?lang=zh_cn&edition=full","pubTime":"2026-10-13 16:06","pubTimestamp":1791878778,"startTime":"0","endTime":"0","summary":"智通财经APP讯,ST人福(600079.SH)发布公告,近日,公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”,公司持有其80%的股权)收到英国药品和健康产品监管局(MHRA)核准签发的舒更葡糖钠注射液的上市许可批准信。舒更葡糖钠注射液获得英国MHRA的上市许可,被批准的适应症为:在成人中拮抗罗库溴铵或维库溴铵诱导的神经肌肉阻滞;对于从出生至17岁的儿科患者,目前仅推荐用于常规拮抗罗库溴铵诱导的阻滞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0185","BK0239","BK0070","600079","BK0012","IPOS","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674822605","title":"ST人福(600079)10月12日主力资金净买入1259.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674822605","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674822605?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:22","pubTimestamp":1791789767,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月12日收盘,ST人福报收于19.65元,上涨2.18%,换手率1.37%,成交量21.07万手,成交额4.13亿元。10月12日的资金流向数据方面,主力资金净流入1259.75万元,占总成交额3.05%,游资资金净流入422.43万元,占总成交额1.02%,散户资金净流出1682.18万元,占总成交额4.07%。ST人福主营业务:药品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200014531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0012","BK0239","BK0028","BK0070","BK0185","BK0188","600079"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674437338","title":"股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674437338","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674437338?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:27","pubTimestamp":1791739629,"startTime":"0","endTime":"0","summary":"公司公告汇总:控股子公司宜昌人福药业盐酸地尔硫片获美国FDA批准,规格覆盖30mg至120mg,用于治疗慢性稳定型心绞痛及冠状动脉痉挛引起的心绞痛。公司公告汇总关于盐酸地尔硫片获得美国FDA批准文号的公告人福医药集团股份公司控股子公司宜昌人福药业有限责任公司近日收到美国食品药品监督管理局关于盐酸地尔硫片的批准文号,ANDA批件号为220590,规格包括30mg、60mg、90mg和120mg。宜昌人福于2025年12月向美国FDA递交上市申请,累计研发投入约1200万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0070","BK0185","BK0239","600079","BK0188","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674500115","title":"股市必读:ST人福新发布《关于盐酸地尔硫?片获得美国FDA批准文号的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674500115","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674500115?lang=zh_cn&edition=full","pubTime":"2026-10-09 01:03","pubTimestamp":1791478989,"startTime":"0","endTime":"0","summary":"公司公告汇总:宜昌人福盐酸地尔硫片获美国FDA批准,规格覆盖30mg至120mg,用于慢性稳定型心绞痛及冠状动脉痉挛引起的心绞痛。公司公告汇总关于盐酸地尔硫片获得美国FDA批准文号的公告人福医药集团股份公司控股子公司宜昌人福药业有限责任公司近日收到美国食品药品监督管理局关于盐酸地尔硫片的批准文号,ANDA批件号为220590,规格包括30mg、60mg、90mg和120mg。宜昌人福于2025年12月向美国FDA递交上市申请,累计研发投入约1,200万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900001408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0188","BK0239","BK0028","BK0070","BK0012","BK0096","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671021022","title":"ST人福(600079)披露2026年度向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺(二次修订稿)的公告,9月29日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671021022","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671021022?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:08","pubTimestamp":1790690901,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘,ST人福报收于18.83元,较前一交易日上涨0.11%,最新总市值为307.35亿元。该股当日开盘18.8元,最高19.0元,最低18.75元,成交额达1.15亿元,换手率为0.39%。近日,ST人福发布《关于公司向特定对象发行A股股票摊薄即期回报与填补措施及相关主体承诺的公告》。控股股东及董事、高级管理人员也就填补回报措施作出相应承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900039756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02843","BK0239","83188","82846","BK1147","BK0185","82843","BK0188","02846","399300","03130","159982","02823","BK0096","82822","82823","BK1610","BK0012","03188","02827","BK0070","600079","BK0028","02822","83130","07233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670840951","title":"股市必读:ST人福新发布《大信会计师事务所(特殊普通合伙)关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670840951","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670840951?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:24","pubTimestamp":1790529852,"startTime":"0","endTime":"0","summary":"大信会计师事务所关于人福医药集团股份公司向特定对象发行股票申请文件的审核问询函的回复公司拟募集资金总额300,000万元至350,000万元,用途同前;大信会计师事务所就募投项目必要性、产能消化风险、财务性投资认定等问题出具核查意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0070","BK0185","BK0239","600079","BK0188","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669056481","title":"ST人福(600079)披露2026年度向特定对象发行A股股票募集说明书(申报稿),9月23日股价上涨0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669056481","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669056481?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:13","pubTimestamp":1790172795,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘,ST人福报收于18.83元,较前一交易日上涨0.53%,最新总市值为307.35亿元。近日,人福医药集团股份公司披露《2026年度向特定对象发行A股股票募集说明书(申报稿)》。公告显示,公司拟向特定对象发行A股股票,募集资金总额不超过35亿元,用于创新药研发、两性健康及复杂制剂制造基地建设、数智化建设及补充流动资金。发行对象为公司控股股东招商生科,构成关联交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300040697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0070","399300","BK0188","02846","159982","83188","BK0028","BK0096","07233","02827","BK1147","BK0239","600079","03130","03188","83130","82846","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667502008","title":"每周股票复盘:ST人福(600079)间苯三酚口崩片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667502008","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667502008?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:29","pubTimestamp":1789234149,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,ST人福报收于18.33元,较上周的18.73元下跌2.14%。本周,ST人福9月7日盘中最高价报18.99元。本周关注点来自公司公告汇总:间苯三酚口崩片获得药品注册证书,批准文号为国药准字H20265842。九珑人福已于2024年12月提交上市申请,累计投入约800万元。该产品获批后将丰富公司产品线,对公司产生积极影响,但未来销售受政策和市场因素影响存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0188","BK0096","600079","BK0070","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794455963381,"stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":-0.0056},{"period":"3month","weight":0.0814},{"period":"6month","weight":0.1031},{"period":"1year","weight":-0.0202},{"period":"ytd","weight":0.1087}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0307},{"period":"3month","weight":-0.0627},{"period":"6month","weight":-0.11},{"period":"1year","weight":-0.0805},{"period":"ytd","weight":-0.0726}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"71771人(较上一季度减少9.00%)","perCapita":"21501股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是以医药工业为主、医药商业为辅。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、黄体酮原料药、祖卡木颗粒、复方木尼孜其颗粒。公司已成长为湖北省医药工业龙头企业、中国医药工业20强、国家企业技术中心、国家技术创新示范企业、中国医药企业制剂国际化先导企业。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}